Cited 13 times in
The safety of stopping nucleos(t)ide analogue treatment in patients with HBeAg-negative chronic hepatitis B
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이혜원 | - |
dc.date.accessioned | 2022-09-06T06:06:02Z | - |
dc.date.available | 2022-09-06T06:06:02Z | - |
dc.date.issued | 2020-03 | - |
dc.identifier.issn | 1478-3223 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/190169 | - |
dc.description.abstract | Background The rates of hepatitis B surface antigen (HBsAg) seroclearance after stopping nucleos(t)ide analogues (NA) in European (19% in 2 years) and Asian (13% in 6 years) patients with chronic hepatitis B (CHB) vary dramatically. We evaluated the incidence of hepatitis flare and HBsAg seroclearance in hepatitis B e antigen (HBeAg)-negative Chinese CHB patients who had stopped NA. Methods This was a territory-wide retrospective study in Hong Kong. We identified HBeAg-negative CHB patients from January 2000 to December 2017 who had stopped NA treatment for more than 3 months. Hepatitis flare was defined as ALT >2xULN. Results The 1076 patients were predominantly middle-aged men (mean age 52 years, male 74.8%) when starting NA; they stopped NA after 82 +/- 35 months of treatment. At 44.3 +/- 24.6 months after stopping NA, 147 (13.6%) patients had hepatitis flare, which led to resumption of NA; whereas 77 (7.2%) patients had flare but did not resume NA. Decompensation occurred in 7/914 (0.8%) patients. A total of 695 (64.6%) patients remained on NA treatment at the last visit. Eleven patients had achieved HBsAg seroclearance (6 of them had hepatitis flare and 1 of these 6 patients achieved HBsAg seroclearance after NA was restarted). Hepatic events developed in 75/695 (10.8%) patients who had NA resumed vs 43/381 (11.3%) patients who did not resume NA (P = .677). Conclusions Hepatitis flare and retreatment were common in HBeAg-negative CHB patients who stopped NA treatment; whereas HBsAg seroclearance rarely occurred. Stopping NA to achieve functional cure should not be recommended at this moment. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Wiley-Blackwell | - |
dc.relation.isPartOf | LIVER INTERNATIONAL | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Antiviral Agents / adverse effects | - |
dc.subject.MESH | DNA, Viral | - |
dc.subject.MESH | Hepatitis B Surface Antigens | - |
dc.subject.MESH | Hepatitis B e Antigens | - |
dc.subject.MESH | Hepatitis B virus / genetics | - |
dc.subject.MESH | Hepatitis B, Chronic* / drug therapy | - |
dc.subject.MESH | Hong Kong / epidemiology | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Symptom Flare Up | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | The safety of stopping nucleos(t)ide analogue treatment in patients with HBeAg-negative chronic hepatitis B | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Grace L-H Wong | - |
dc.contributor.googleauthor | Henry L-Y Chan | - |
dc.contributor.googleauthor | Becky W-Y Yuen | - |
dc.contributor.googleauthor | Yee-Kit Tse | - |
dc.contributor.googleauthor | Hester W-S Luk | - |
dc.contributor.googleauthor | Terry C-F Yip | - |
dc.contributor.googleauthor | Vicki W-K Hui | - |
dc.contributor.googleauthor | Lilian Y Liang | - |
dc.contributor.googleauthor | Hye-Won Lee | - |
dc.contributor.googleauthor | Grace C-Y Lui | - |
dc.contributor.googleauthor | Vincent W-S Wong | - |
dc.identifier.doi | 10.1111/liv.14330 | - |
dc.contributor.localId | A03318 | - |
dc.relation.journalcode | J02171 | - |
dc.identifier.eissn | 1478-3231 | - |
dc.identifier.pmid | 31845462 | - |
dc.identifier.url | https://onlinelibrary.wiley.com/doi/10.1111/liv.14330 | - |
dc.subject.keyword | antiviral treatment | - |
dc.subject.keyword | chronic hepatitis B | - |
dc.subject.keyword | HBsAg | - |
dc.subject.keyword | HBV | - |
dc.contributor.alternativeName | Lee, Hye Won | - |
dc.contributor.affiliatedAuthor | 이혜원 | - |
dc.citation.volume | 40 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 549 | - |
dc.citation.endPage | 557 | - |
dc.identifier.bibliographicCitation | LIVER INTERNATIONAL, Vol.40(3) : 549-557, 2020-03 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.